Therapies directed against tumor-associated macrophages that modulate the degree of immunosuppression hold translational potential.41,56 While still at an early stage, immunotherapy that specifically targets tumor inflammation may emerge as a new class of NF2 therapeutics. Here, NF2 is linked to neoplasm.